Clinical Trial Update: A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 1/Phase 2 study of an anti-CD19 CAR-T cell therapy for refractory/relapsed B-cell malignancies, including acute ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19-targeted CAR-T cell therapy

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN